Oncol 2007 ; 25 : 1043 – 1047 . 71 Garneski KM Nghiem P . Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy . J Am Acad Dermatol 2007 ; 57 : 166 – 169 .
Search Results
Merkel Cell Carcinoma: A Review of Current Advances
Frank Qian Zhan, Vathani Sharon Packianathan, and Nathalie Charlotte Zeitouni
Local Excision for Rectal Cancer
John M. Skibber
-1064 . 36 Balani A Turoldo A Braini A . Local excision for rectal cancer . J Surg Oncol 2000 ; 74 : 158 - 162 . 37 Garcia-Aguilar J Mellgren A Sirivongs P Buie D . Local excision of rectal cancer without adjuvant therapy: a word of
Differences in Patient Screening Mammography Rates Associated With Internist Gender and Level of Training and Change Following the 2009 U.S. Preventive Services Task Force Guidelines
Dawn J. Brooks
, 2015 . 2. Berry DA Cronin KA Plevritis SK Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators . Effect of screening and adjuvant therapy on mortality from breast cancer . N Engl J Med 2005 ; 353 : 1784 – 1792
Updates in the Systemic Therapy Options for Clear Cell and Non–Clear Cell Renal Cell Carcinoma
Presented by: Philippe E. Spiess, Peter A.S. Johnstone, and Eric Jonasch
4. Powles T , Tomczak P , Park SH , Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo
New Treatment Options for Patients With Bladder Cancer
Presented by: Thomas W. Flaig
, preferred regimens in this setting are enfortumab vedotin and erdafitinib. 3 According to Dr. Flaig, the NCCN Guidelines also provide recommendations for adjuvant therapy. “In the past, we have simply [considered] chemotherapy if patients had not received
New Systemic Treatment Options for Hepatobiliary Cancers
Presented by: Robin Kate Kelley
(ClinicalTrials.gov identifiers: NCT03847428, NCT03383458, NCT04102098, NCT03867084). Currently, there is no role for adjuvant therapy after resection or ablation in HCC. “Lastly, an important point to look forward to in the field is the combination of ICIs with
Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options
Presented by: Margaret A. Tempero
with adjuvant therapy in the setting of resected pancreatic adenocarcinoma. Although there was an effort to try to improve median OS, it wasn’t until we got to…gemcitabine and capecitabine that we were beginning to see some improvement,” Dr. Tempero
Current Approaches in Hereditary Nonpolyposis Colorectal Cancer
Patrick M. Lynch
from epigenetic hypermethylation of the hMLH1 promoter, and also typically showing BRAF mutation) are worth detecting because of differences in prognosis and response to adjuvant therapies that include 5-FU. 14 This is the position of the EGAPP. 15
Treatment of Non–Small Cell Lung Cancer in the Older Patient
Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria
cisplatin plus vinorelbine after resection of stage IB and II NSCLC) found that older patients received lower cumulative doses of the agents secondary to issues with tolerability. 24 Despite this, however, the benefit seen with adjuvant therapy in older
Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study
Christopher M. Booth, Sulaiman Nanji, Xuejiao Wei, Yingwei Peng, James J. Biagi, Timothy P. Hanna, Monika K. Krzyzanowska, and William J. Mackillop
access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. References 1. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer . JAMA
